# A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

> **NCT05988008** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 80 (actual)

## Conditions studied

- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

## Interventions

- **DRUG:** CCX168
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05988008
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2018-01-26
- **Final completion:** 2018-09-20
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05988008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05988008, "A Study of CCX168 in Japanese and Caucasian Healthy Adult Males". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05988008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*